Meeting
2013 ASCO Annual Meeting
Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM).
Authors
Ulrik Niels Lassen
Rigshospitalet, Copenhagen, Denmark
Ulrik Niels Lassen , Oliver L. Chinot , Catherine McBain , Morten Sorensen , Vibeke Andree Larsen , Maryline Barrie , Patrick Roth , Oliver Krieter , Karen Wang , Kai Habben , Jean Tessier , Angelika Lahr , Matt Whiley , Michael Weller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01308684
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2092)
DOI
10.1200/jco.2013.31.15_suppl.2092
Abstract #
2092
Poster Bd #
7H
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Updated safety phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM.
First Author: Michael Lim
Poster
2016 ASCO Annual Meeting
A phase I study of MLN0128 and bevacizumab in patients with recurrent glioblastoma and other solid tumors.
First Author: Lakshmi Nayak
Poster
2016 ASCO Annual Meeting
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
First Author: Kent C. Shih
Poster
2015 ASCO Annual Meeting
Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.
First Author: Annick Desjardins